The African trypanosome Trypanosoma brucei spp. is a paradigm for antigenic variation, the orchestrated alteration of cell surface molecules to evade host immunity. The parasite elicits robust antibody-mediated immune responses to its variant surface glycoprotein (VSG) coat, but evades immune clearance by repeatedly accessing a large genetic VSG repertoire and 'switching' to antigenically distinct VSGs. This persistent immune evasion has been ascribed exclusively to amino-acid variance on the VSG surface presented by a conserved underlying protein architecture. We establish here that this model does not account for the scope of VSG structural and biochemical diversity. The 1.4-Å-resolution crystal structure of the variant VSG3 manifests divergence in the tertiary fold and oligomeric state. The structure also reveals an O-linked carbohydrate on the top surface of VSG3. Mass spectrometric analysis indicates that this O-glycosylation site is heterogeneously occupied in VSG3 by zero to three hexose residues and is also present in other VSGs. We demonstrate that this O-glycosylation increases parasite virulence by impairing the generation of protective immunity. These data alter the paradigm of antigenic variation by the African trypanosome, expanding VSG variability beyond amino-acid sequence to include surface post-translational modifications with immunomodulatory impact.
A ntigenic variation, or the diversification of expressed surface antigens during the course of infection, is a microbial survival strategy exemplified by the African trypanosome (Trypanosoma brucei spp.), the causative agent of African sleeping sickness in humans and nagana in livestock. Central to this immune-evasion strategy is the variant surface glycoprotein (VSG) coat of ~10 million molecules that densely covers the organism in its mammalian-infectious forms. The VSG coat elicits a robust antibody response, which the parasite evades by 'switching' to a new, antigenically distinct variant. The VSG-antibody interaction thus represents the central molecular interface between the T. brucei pathogen and its host, resulting in observable peaks and valleys of parasitaemia that are the repeated outcome of cycles of VSG switching, antibody generation and parasite killing 1 .
Despite the centrality of the VSG-antibody interaction, the key parameters involved remain poorly characterized, such as how antibodies might bind the dense VSG surface array, and how the sequence diversity between VSG genes manifests structurally to allow continual evasion of accumulated antibody responses during infection 2, 3 . Long-held assumptions have ascribed the immune-evasive properties of new coats exclusively to divergence in the amino-acid sequence of VSG antigenic surfaces displayed on a scaffold of conserved overall architecture. This view was first formed nearly three decades ago on the basis of crystal structures of the amino (N)-terminal domains (NTDs) of two VSGs 4,5 . These early structural analyses revealed three key features: a general conservation of architecture consisting of a two-lobed, 'dumbbell' arrangement, the 'top' (facing away from the pathogen) and 'bottom' regions separated by an elongated three-helix bundle (Fig. 1a) ; the VSGs formed homodimers; and despite alignment in the three-dimensional folds of these molecules (particularly in the core helical bundle), their surface properties varied considerably, consistent with the generation of immunologically distinct entities.
Structural information and VSG sequence alignments have been used to allocate VSG NTDs to different classes based on the presence of numerous analogous cysteine disulfides 6 . The two early VSG structures, VSG2 (also termed MITat1.2 and VSG221) and ILTat1.24, and a newer structure published during review of this manuscript (VSG M1.1, which is highly homologous to VSG2 7 ) all belong to class A. Given the depth of the genomic archive and the substantial diversity within VSGs even at the level of primary sequence, it seemed unlikely that the three structures published to date would exhaustively cover variation in VSG protein space.
Here, we present the crystal structure of the NTD of a common class B variant, VSG3 (also termed MITat1.3 and VSG224), which contains several distinct structural and biochemical features as compared to previously published VSGs. Most notably, an unexpected O-linked glycan was identified in the VSG3 crystal structure at residue Ser 317, located on the top surface of the NTD. Mass spectrometry (MS) analyses revealed heterogeneity in the number of hexoses linked to VSG3 Ser 317, and also that analogous modifications are present in other class B VSGs. Finally, mouse infection and
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antibody binding assays showed that the VSG3 O-glycan potently increases parasite virulence and impairs the host's ability to generate a protective antibody response against trypanosomes expressing a VSG3 surface coat.
Results
Structural and oligomeric divergence in the VSG3 NTD. Preliminary examinations of VSG3 showed that it not only differs markedly at the sequence level from VSG2, ILTat1.24 and VSG M1.1 but that it also scored poorly against these structures in structurebased prediction algorithms such as protein 'threading' 8 . Intrigued by these analyses, we proceeded to crystallize and solve the structure of this variant (Methods and Supplementary Table 1 ). The 1.4-Å-resolution crystal structure reveals that although VSG3 shares the overall two-lobe, three-helix bundle architecture with the class A VSGs, there is substantial divergence in the fold as well as the topology, such as the connectivity of the lower-lobe subdomain ( Fig. 1 and Supplementary Fig. 1 ). Consistent with such variation, the oligomerization state of the VSG3 NTD is also different, existing in solution and the crystal asymmetric unit as a monomer rather than a dimer ( Supplementary Fig. 2) 4, 5, 7 . Further divergence from previous VSG structures is found in the number and location of cysteine disulfide bonds in the top lobe of the protein ( Supplementary Fig. 3 ), including one that anchors an antigenically critical loop (discussed below), as well as the position and structural context of an N-linked glycan in the lower lobe ( Fig. 2a and Supplementary Fig. 4 ).
VSG3 is heterogeneously O-glycosylated.
A striking feature of the VSG3 structure is an unexpected carbohydrate modification ( Fig. 2a,b ). Additional density attached to Ser 317 revealed the presence an O-linked α -glucose moiety (Fig. 2b ). This modification is located on the top surface of VSG3 in an exposed loop stabilized by flanking cysteines involved in a disulfide bridge (the peptide CTGSASEGLC, residues 314-323, Fig. 3a ), and is therefore likely to be highly accessible to the immune system. Analysis of intact VSG3 by electrospray MS before and after digestion with PNGaseF validated the O-linked α -glucose moiety identified in the crystal structure, and also revealed heterogeneity in the number of O-linked glycans present ( Supplementary Fig. 5 ). Subsequently, peptide mass analysis by liquid chromatography with tandem MS (LC-MS/MS) confirmed that the peptide Ala 311-Lys 339 contained 0, 1, 2 or 3 hexose residues (Fig. 3b ), and the MS/MS product ion spectra of several peptide glycoforms further defined the O-glycosylation site as Ser 317 ( Supplementary Fig. 6 ). Together, these data strongly suggest that there is a heterogeneous chain of 0-3 hexoses attached to Ser 317. On the basis of the electrospray MS spectra ( Supplementary Fig. 5a ,b), we estimate the proportions of the 0, 1, 2 and 3 hexose glycoforms at 8%, 33%, 37% and 22%, respectively. No evidence of additional glycosylation of serines or threonines was observed.
While the modification of serine and threonine residues by O-and phosphodiester-linked carbohydrate chains is known for other kinetoplastids 9 , such modifications have not previously been described in T. brucei. To our knowledge, this is also the first description of a Glcα 1-O-Ser linkage in any organism, although Glcβ 1-O-Ser linkages are known 10 . In addition, no carbohydrate of any kind has previously been shown to occur on the top surface of any VSG.
Other VSGs display analogous O-linked glycans.
To assess the prevalence of surface O-linked glycosylation, we compiled a list of VSGs from diverse genomic locations 11 with NTDs that threaded to VSG3 and contained cysteine-flanked, serine-or threonine-containing loops analogous to the glycosylated loop in VSG3. A subset of this list is shown in Fig. 3c . We then analysed two of these: VSG11 and VSG615. We also examined VSG21, which fails to thread to VSG3. MS analysis showed that both VSG11 and VSG615 possessed heterogeneous O-linked hexose modifications analogous to those found in VSG3 ( Fig. 3d,e ), whereas VSG21 did not. These data suggest that surface O-linked glycosylation could be a widespread VSG modification present throughout trypanosome infections.
The VSG3 O-glycan enhances parasite virulence. As a result of its central placement on the top surface of VSG3, we hypothesized that the O-linked glycan might constitute a critical antigenic determinant. To test this conjecture, we genetically engineered isogenic trypanosome strains that carried either a wild-type VSG3 (VSG3 WT ) coat or a VSG3 coat with a S317A point mutation (VSG3 S317A , which cannot be O-glycosylated). This was achieved by knocking the genes for these coats into a VSG2 expression site, replacing the active VSG2 gene (Methods and Supplementary Fig. 7 ). We then used these strains to infect naive C57BL/6 mice.
The polyclonal antibodies that mediate T. brucei clearance are of IgM class and directed solely against exposed epitopes of a b parasite-bound VSG 12 . To compare the ability of the two isogenic strains to evade this IgM response, we focused on the first peak of parasitaemia (up to day 9 post-infection). During this period, outgrowth of the VSG3 WT/S317A -expressing trypanosomes occurs, and mice either succumb to infection or clear the parasite population, leaving only those cells that have switched expression to a new VSG. We observed that all VSG3 WT -infected animals succumbed to infection during the first peak ( Fig. 4a ). In contrast, all but one of the VSG3 S317A -infected animals survived the first peak, having cleared the VSG3 S317A -expressing trypanosomes by day 8. Late mortality events (after day 10) in the VSG3 S317A mouse group resulted from outgrowth of parasites that had switched expression to other VSGs. This robust differential in virulence was reproducible in two independent clone sets (data from the two clone sets are combined in Fig. 4a and shown separately in Supplementary Fig. 8a ,c), and in additional infections of a different mouse strain (CD-1; Supplementary Fig. 8e ). We also observed lower peak parasitaemia levels in the VSG3 S317A infections compared to the VSG3 WT infections ( Fig. 4b and Supplementary Fig. 8b ,d,f). However, growth curves between the wild-type and mutant VSG3 trypanosomes were similar in vitro ( Supplementary Fig. 7b ), suggesting that the differences observed in infection were related to host factors rather than being clone-intrinsic. We therefore reasoned that our infection data might reflect a role for the VSG3 O-linked glycan chains in inhibiting the host's ability to generate a protective antibody response.
VSG3 O-glycosylation impairs host development of protective immunity. To address this hypothesis, we performed additional infection experiments in which mice were immunized against VSG3 WT or VSG3 S317A before infection (via inoculation with ultraviolet-irradiated parasites-see Methods). This protocol was previously shown to yield an immune response that closely mimics the response to the infective parasite 13 . We then challenged these mice via injection of live cognate parasites at day 8 post-immunization and monitored mouse blood smears for the presence of trypanosomes on days 5-8 post-challenge. As shown in Fig. 4c , nonimmunized mice (Fig. 4a,b ) uniformly presented parasitaemia by day 5. We found that pre-immunization with VSG3 S317A was highly protective, suppressing detectable outgrowth of cognate VSG3 S317A trypanosomes in 83.3% (10/12) of mice ( Fig. 4c ). In contrast, preimmunization with VSG3 WT was only marginally protective against cognate VSG3 WT trypanosomes, suppressing outgrowth in 25% (3/12) of mice. All mice that presented parasitaemia either succumbed to infection or cleared the parasites by day 8. The discrepancy in the protective effect of pre-immunization was also evident in survival differences between the two mouse groups ( Supplementary  Fig. 9a ). These results provide evidence that the O-linked glycan chains displayed by VSG3 inhibit the ability of the host antibody response to mediate parasite clearance.
To directly examine the effect of the O-glycan chains on the properties of polyclonal IgM responses, we collected antisera elicited by VSG3 WT -or VSG3 S317A -coated parasites at day 8 post-infection. We then used flow cytometry (fluorescence-activated cell sorting (FACS)) analysis to assess antisera binding in the context of the intact parasite surface coat (as surface binding is thought to be necessary and sufficient to predict clearance 12 ). In accordance with our in vivo results, we found that VSG3 WT -elicited antisera exhibited markedly lower binding against VSG3 WT trypanosomes, as compared to VSG3 S317A -elicited antisera binding VSG3 S317A trypanosomes ( Fig. 4d ,e; Supplementary Fig. 9b-f ). Additional analyses of the cross-reactivities of our polyclonal antisera did not suggest a simple mechanistic explanation as to how the heterogeneous O-glycan chains cause elicitation of IgM responses that are poorly functional against cognate VSG3 WT coats ( Supplementary Fig. 9b-f ). VSG3 WT -elicited antisera bind VSG3 S317A -expressing parasites well, which weakens the explanation that O-glycosylation simply causes elicitation of antibodies that are poorly functional. In the reverse combination, VSG3 S317Aelicited antisera also bind VSG3 WT -expressing parasites well, indicating that the O-glycosylation is not broadly able to inhibit antibody binding. These data therefore suggest that the poor binding of the WT/WT parasite/antisera combination may result from a combined effect of the heterogeneous O-glycan chains at both the antibody elicitation stage and in the subsequent antibody-parasite interactions (discussed further below). Despite the apparent complexity of the underlying mechanism, the clear and accordant O-glycan-dependent discrepancies observed in parasite clearance following infection ( Fig. 4a ), generation of protective immunity from pre-immunization ( Fig. 4c ) and cognate antibody binding ( Fig. 4e ,f) together strongly indicate that the O-glycan chains that decorate VSG3 aid the parasite in evasion of the host's humoral immune response.
Discussion
The African trypanosome presents a fascinating paradigm for persistent immune evasion through antigenic variation. The discovery of the VSGs and of VSG coat switching dramatically altered our understanding of African trypanosomiasis and opened vistas for research into understanding how a pathogen can continuously avoid the ever-adapting mammalian immune system. Sequence analyses and some structural studies have provided many key insights into the bases of antigenic diversity between VSGs. However, the results we present in this study indicate that our understanding of VSG diversity at the protein level has been (and almost certainly remains) incomplete. We have demonstrated that VSG structural architecture is more variable than initially appreciated, expanding the VSG 'diversity space' at the level of the protein fold and resulting molecular surfaces. Unexpectedly, we have also identified a VSG Supplementary Fig. 9 ), it is important to first reiterate that these analyses represent overall functionality of polyclonal antisera. These antisera are comprised of a multitude of clonal antibodies (of IgM class), each exhibiting distinct properties. The factors influencing the overall reactivity of the polyclonal antisera thus include: the binding epitope of each antibody; whether the epitopes overlap with or are affected by the glycan, and if so, whether the glycan affects each interaction enough to significantly alter antibody binding; and, finally, the abundance of each monoclonal IgM antibody within the population of antibodies that make up the polyclonal antisera. The subject of the effects of glycosylation on antibody binding is a poorly understood area, complicated by the diverse ways glycosylation can alter the antigenic character of the modified protein.
Relevant literature demonstrates that glycosylation of proteins and peptides can have myriad effects on the binding profile of antibodies that target regions in the vicinity of the glycan(s), extending beyond simple exposure or occlusion of epitopes (reviewed previously 14 ). An individual antibody raised against a glycoprotein may have unaffected, increased or decreased binding affinity based on the presence or absence of the glycan, the length and composition of the glycan chain, and 'allosteric' effects of the glycan on the structural conformation of the surrounding peptidic regions (that is, the affected epitope need not actually include the glycan). The impact of differential glycosylation can vary dramatically and unpredictably for individual antibodies 15 .
The fact that VSG3 is variably modified with a chain of zero to three O-linked hexoses may also suggest that display of a heterogeneously glycosylated surface can impair immune function. Heterogeneous O-glycosylation of VSG3 would be expected to produce, minimally, four antigenically variable entities on the trypanosome surface (one for each hexose chain length, ignoring the possibility of multiple conformers for each chain). These multiple glycoforms would therefore present a more diverse set of epitopes for antibody elicitation and a less homogeneous surface for antibody binding. Furthermore, IgM antibodies are particularly sensitive to epitope density because their binding is typically dependent on polyvalent interactions. For T. brucei specifically, effective IgM binding and trypanosome clearance have been demonstrated to require a critical density of cognate VSGs on the trypanosome surface 13 . The presence of various glycoforms on a VSG3 WT coat could reduce the effective densities of any epitopes altered by glycosylation. In contrast, a VSG3 S317A coat would be comparatively homogeneous and potentially more amenable to binding for IgMs with certain specificities.
Overall, because of the complexity of the system and the quantity of unknown variables, it is impossible to predict a priori the prevalence or proportions of elicited antibodies in our antisera with given binding epitopes, glycoform specificities, affinities and avidities, but these are some of the factors that underlie our binding results in aggregate. The mechanisms contributing to our results could be further examined by isolating a set of monoclonal antibodies from the polyclonal responses and testing their binding properties against different VSG3 glycoforms, or potentially VSG3-derived peptide glycoforms. Importantly however, the binding effects observed probably depend on multiple epitopes and the overall structure and packing of VSGs in the surface coat. Such studies could improve our understanding of the impact of glycosylation on the antibody response, a topic with relevance far beyond T. brucei infection.
In summary, our data demonstrate unexpected antigenic variation in T. brucei VSG coats that cannot be predicted by primary sequence analysis. Beyond significant additional variation in the protein fold, the high-resolution structure of VSG3 reveals an unanticipated (and potentially widespread) post-translational modification on the VSG surface that potently enhances parasite immune evasion. Antigenic variation in the African trypanosome therefore includes multiple overlapping immune evasion strategies: aminoacid divergence, heterogeneous surface glycosylation and perhaps additional variance yet to be uncovered.
Methods
Purification of VSGs. T. brucei expressing VSG2, VSG3, VSG3-S371A mutant, VSG11, VSG21 or VSG615 were cultured in vitro in HMI-9 16 media. Cells were pelleted and then lysed in 0.2 mM ZnCl 2 , according to established protocols 17 . This lysis mixture was centrifuged, and the pellet containing the membrane material was resuspended in pre-warmed (40 °C) 10 mM phosphate buffer. This enabled activation of endogenous lipases and resulted in the efficient release of surface VSG protein from the membrane. Following a second centrifugation, supernatant containing VSG3 protein was loaded onto an anion-exchange column (Q-Sepharose Fast-Flow, GE Healthcare), which had been equilibrated with 10 mM phosphate buffer. Two passes through this column resulted in the carboxy-terminal truncation of VSG3 (but not VSG2), presumably due to cleavage by endogenous proteases. This C-terminally truncated VSG3 was more stable than full-length VSG3 and was used for crystallization. Further purification steps for VSG3 include one or, if necessary, two runs over a gel filtration column (Superdex 200, GE Healthcare) in 10 mM HEPES pH 7.5 ((4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)), 150 mM sodium chloride (NaCl). Aliquots from the gel filtration runs were subjected to SDS-PAGE analysis for visual inspection.
Crystallization and structural determination. For crystallization, the purified VSG3 N-terminal domain was concentrated to 2 mg ml −1 in a buffer containing 10 mM HEPES pH 7.5, 150 mM NaCl. Native crystals were grown by vapour diffusion using hanging drops formed from mixing a 1:1 volume ratio of the protein with an equilibration buffer consisting of 16-22% polyethylene glycol (PEG) molecular weight 3,350 Da, 200-325 mM NaCl and 100 mM Tris pH 8.2 (tris(hydroxymethyl)aminomethane). For cryoprotection, crystals were transferred directly into a buffer with a 25% PEG 3350 Da, 300 mM NaCl, 100 m Tris pH 8.2, 10% glycerol and flash-cooled immediately afterward to 100 K (− 173.15 °C). Crystals formed in the space group I23 with a single VSG3 monomer in the asymmetric unit. For phase determination, crystals were grown in similar conditions in which NaCl was replaced with sodium bromide (18-22% PEG 3,350 Da, 275-400 mM sodium bromide, 100 mM Tris pH 8.2). Before flashfreezing, those crystals were transferred into cryoprotection buffers (25% PEG 3,350 Da, 50 mM Tris pH 8.2, 5% glycerol) containing a stepwise increasing concentration of sodium bromide from 0.5 M to 2 M.
Data were collected at the Advanced Photon Source at Argonne National Laboratory at beamline 24-ID-C and processed on-site through the RAPD software pipeline [18] [19] [20] [21] [22] . Bromine-soaked crystals were collected at a wavelength of 0.9194 Å and the structure was solved by single-wavelength anomalous dispersion from the anomalous signal due to 28 partially ordered bromine ions using the SHELX suite 23 . A partial model of the bromine-soaked protein was built by the PHENIX suite 24 . This model was then used in arp/wARP 25, 26 Preparation of O-glycopeptides. Purified VSG3 (50 µ g in 25 µ l 10 mM sodium phosphate, pH 8) was reduced (10 mM DTT, 85 °C, 20 min), S-alkylated (25 mM IAA, for 1 h, at room temperature, in the dark), diluted with an equal volume of 2 × GluC buffer and digested with 1:25 (w/w) endoproteinase GluC (New England BioLabs) for 24 h, at 37 °C, with shaking. The GluC fragments were separated using NuPAGE 4-12% Bis-Tris protein gels (Invitrogen), stained with Coomassie brilliant blue (Thermo Scientific) and the 17 kDa fragment was excised and subjected to in-gel trypsin digestion for LC-MS/MS analysis.
LC-MS/MS analysis of glycopeptides. The LC instrument was an Ultimate U3000 Nano LC System (Dionex) fitted with a C18 trap (PepMap nanoViper, Thermo Scientific) and a resolving column (PepMap RSLC) with inner diameters of 100 and 75 µ m and lengths of 2 and 50 cm, respectively. The mobile phases were 0.1% formic acid in 2% acetonitrile (solvent A) and 0.08% formic acid in 80% acetonitrile (solvent B). The samples were loaded in solvent A and eluted as follows: 0% B for 5 min, gradient to 40% B in 122 min and to 98% B in 10 min, held at 98% B for 20 min, followed by 20 min re-equilibration with 2% B. The LC system was coupled to an LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific) equipped with an Easy Spray ion source and operated in positive-ion mode. The spray voltage was 2 kV and the full scans were acquired in a Fourier transform MS mass analyser over m/z 335-1800 at a resolution of 60,000. The MS/MS analyses were performed under data-dependent mode to fragment the top 15 precursors using collision-induced dissociation. The raw files, converted to mgf format by MSConvert (http://proteowizard.sourceforge.net), were searched against the VSG3 protein sequence using Mascot software 30 with the parameters set as follows: peptide tolerance, 5 ppm; MS/MS tolerance, 0.5 Da; enzyme, trypsin; one missed cleavage allowed; and fixed carbamidomethyl modifications of cysteines. Oxidation of methionine and serine conversion to de-hydro alanine were used as variable modifications.
LC-MS analysis of intact and de-N-glycosylated VSG3. VSG3 (50 µ g) was denatured in 1% sodium dodecyl sulphate for 10 min at 95 °C and then digested with 2,500 units of glycerol-free N-glycosidase F (PNGaseF, NEB) in 1% n-octyl-β -d-glucopyranoside for 24 h at 37 °C. The de-N-glycosylated product was precipitated in 10% trichloroacetic acid for 24 h at 4 °C, collected by centrifugation (16,000g, for 20 min, at 4 °C), washed with cold acetone, air-dried and redissolved in 1% formic acid. A control (non-treated) VSG3 sample was similarly trichloroacetic acid-precipitated and redissolved in 1% formic acid. The samples were analysed by LC-MS using an Agilent 1200 System fitted with a C8 column (Agilent), with an inner diameter of 25 µ m and a length of 360 mm. The mobile phases were the same as above. The samples were loaded in solvent A and eluted as follows: 7% B for 8 min, gradient to 25% B in 25 min and to 60% B in 48 min, held at 60% B for 10 min, followed by 10 min re-equilibration with 7% B. The LC system was coupled to an Agilent 6520 Q-Tof mass spectrometer. The spray voltage was 1.7 kV and the ion transfer tube was set at 360 °C. MS scans were collected over m/z 335-3,200 and spectra were deconvoluted using the Maximum Entropy software with the settings mass range 35-45K; mass step, 1.0 Da; S/N threshold, 30; adduct, proton; average mass, 90% peak height; maximum consecutive charge state, 5; and minimum protein fit score of 8.
Cloning of VSG3 and VSG3-S317A knock-in vectors pKI224 and pKI224-S317A. Plasmid cloning was performed as follows: first, the wild-type VSG3 gene was amplified from trypanosomal genomic DNA (Lister427) into a pGEM subcloning vector (Promega A1360), and the S317A mutation was introduced by QuikChange PCR. Wild-type and mutant VSG3 genes were then cloned into the vector pUB39 31 (replacing VSG117 in the original vector via HindIII and BamHI sites) to create pSUN7 and pSUN8. VSG3 and VSG3-S317A were amplified from pSUN7 and pSUN8, respectively, using primers 224_BsiWI_For (5′ -GCGACACGTACGCGGCATGCAAGCGGCAGCA-3′ ) and 224_AvrII_Rev (5′ -AATTAACCTAGGGGGCAATTCCAGCTGTC-3′ ) (these PCR fragments contained the WT/S317A VSG3 coding regions along with the surrounding VSG117 5′ and 3′ untranslated regions from the pUB39 vector). The backbone vector pSY37F1D-CTR-BSD was digested with BsiWI and SpeI, and the larger fragment was isolated by gel purification. VSG3 and VSG3-S317A PCR fragments were digested with BsiWI and AvrII and ligated into the pSY37F1D-CTR-BSD fragment, resulting in final plasmids pKI224 and pKI224-S317A, respectively.
Generation of VSG3 WT and VSG3 S317A -expressing T. brucei. The wild-type VSG3
and VSG3-S371A point-mutant genes were transfected into trypanosomes by means of the previously established pSY37F1D-CTR-BSD vector 13 . This vector contains a blasticidin-resistance gene (BSD) cassette and allows a 'knock-in' transfection in which the VSG gene included in the vector replaces the endogenous VSG2 gene in the telomeric bloodstream-form expression site 1 (BES1) of the Lister427 genome (see diagram, Supplementary Fig. 7a ). First, the wild-type VSG3 and VSG-S317A point-mutant genes were cloned into the PSY37F1D-CTR-BSD vector backbone to create plasmids pKI224 and pKI224-S317A, respectively. These plasmids were then linearized with XhoI and transfected into a parental clone expressing VSG2 via the Amaxa nucleofector protocol as previously described 32 . BSD resistant clones were selected on the basis of expression of VSG3 (by FACS) and counterselected for dual expressors (which co-expressed VSG2; also by FACS), using monoclonal antibodies against VSG2 and VSG3. VSG2 counterselection was used to eliminate a subset of clones that integrated the VSG cassette ectopically. Two sets of clones were generated. Transfection of VSG3 and VSG3-S317A into the Lister 427 'single marker' cell line 33 produced clones KI.VSG3 WT -1 and KI.VSG3 S317A -1, respectively. Transfection of VSG3 and VSG3-S317A into a different VSG2-expressing Lister 427 cell line (GPI-PLC null 34 ) produced clones KI.VSG3 WT -2 and KI.VSG3 S317A -2, respectively. KI.VSG3 WT -2 and KI.VSG3 S317A -2 were generated on a GPI-PLC −/− background. The lack of a GPI-PLC gene does not affect parasite virulence or the course of parasitaemia 34 and consequently should not affect interpretation of the mouse infection results shown. The presence of the single point mutation within VSG3 S317A was verified in the KI.VSG3 S317A clones through real-time PCR amplification and sequencing. Fig. 4a,b , groups of C57BL/6J or CD-1 mice were infected via intraperitoneal (i.p.) injection of 100 live trypanosomes, expressing either VSG3 WT or VSG3 S317A . For Fig. 4c and Supplementary Fig. 9a , immunization-challenge experiments were performed as previously described 13 using C57BL/6 J mice. For immunization, mice received an i.p. injection with 2-3 × 10 6 ultraviolet-irradiated trypanosomes (KI.VSG3 WT -2 or KI.VSG3 S317A -2; these clones lack the endogenous lipase GPI-PLC, and therefore retain intact VSG coats following irradiation 34 ) in 100 μ l HMI-9, and an identical repeat injection 3 days later. The subsequent challenge injection was administered 8 days after the initial immunization, and consisted of 100 live trypanosomes (as in the experiments in Fig. 4a,b ). For all infection experiments, mouse survival was assessed daily, and parasitaemia was monitored starting on day 4 or 5 by blood smear (blood from mouse tail clippings examined under a microscope for the presence of trypanosomes) or by counting parasite numbers using a haemocytometer. For Fig. 4c , mice were permanently scored as 'confirmed parasitaemia' when parasites were first identified by blood smear, regardless of whether parasitaemia subsequently fell to undetectable levels. All mice were wild-type males or females, aged 6-9 weeks at the start of the experiment (Jackson Laboratory). We did not have an a priori, pre-specified effect size from which to preemptively determine an appropriate sample size for our mouse infection experiments, but the sample sizes were determined to be large enough to ensure proper statistical analyses and reproducibility. Mice were assumed to be sufficiently randomized by Jackson Laboratory and no additional randomization was performed. Experimenters were not blinded to mouse group allocation, but measurements (survival assessment, parasitaemia counts and FACS MFI) were not subjective. All animal experiments were approved by Rockefeller University's institutional animal care and use committee under protocol no. 16894.
Mouse infection assays. For
Elicitation of VSG3 WT and VSG3 S317A -specific polyclonal IgM antisera. C57BL/6J mice were injected i.p. with 1 × 10 3 VSG3 WT or VSG3 S317A -expressing trypanosomes in HMI-9 (three mice each). After 4 days, infections were cleared with 250 μ g berenil per mouse injected i.p., and berenil treatment was repeated after 24 h. Clearance was necessary to prevent VSG3 WT -infected animals from succumbing to infection before developing significant antibody titres. On day 8 post-injection, blood was collected via cardiac puncture, and serum was separated from whole blood using Microtainer serum collection tubes (BD 365967).
FACS analyses to determine IgM binding. All samples, solutions and incubation steps were at 4 °C or on ice to prohibit antibody internalization during sample preparation. One million VSG3 WT or VSG3 S317A -expressing trypanosomes were isolated from culture, resuspended in HMI-9 containing dilutions of VSG3 WT or VSG3 S317A -specific polyclonal IgM antisera (see above), and incubated for 10 min. Cells were washed once with HMI-9, and then incubated with a 1:1,000 dilution of goat anti-mouse IgM-fluorescein isothiocyanate (FITC) (SouthernBiotech 1021-02) in HMI-9 for 10 min. Cells were washed once again with HMI-9, resuspended in HMI-9 containing 500 ng ml −1 propidium iodide (BD 556463) (for exclusion of dead cells from analysis) and analysed using a BD-FACSCalibur (Fig. 4c) or a BD-LSRII flow cytometer ( Fig. 4d ) and FlowJo software (Treestar). A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
Crystallographic data collected at Advanced Photon Source (APS) at Argonne National Laboratory at beamline 24-ID-C and processed onsite through the RAPD software pipeline. Flow cytometry data was collected using FACSDiva software (BD Biosciences).
Data analysis
Crystallographic data collected at Advanced Photon Source (APS) at Argonne National Laboratory at beamline 24-ID-C and processed onsite through the RAPD software pipeline. Bromine SAD phasing was calculated using the SHELX suite. A partial model of the brominesoaked protein was built by the PHENIX suite. This model was then used in arp/wARP as a starting model for automated building against the native data to 1.4A resolution. Several cycles of automated building with arp/wARP, refinement with REFMAC, and manual inspection and model building led to a final model with and R/Rfree of 13.0%/16.9%.
LC-MS/MS analysis of glycopeptide raw files, converted to mgf format by MSConvert (proteowizard.sourceforge.net), were searched against the VSG3 protein sequence using the Mascot software (v.2.4.0, Matrix Science Inc., Boston, MA). LC-MS analysis of intact and de-N-glycosylated VSG3 scans were collected over m/z 335-3200 and spectra were deconvoluted using the Maximum Entropy software.
Flow cytometry data was analyzed using FlowJo software. Data plotting and statistical analyses were performed using Prism (Graphpad) and R.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Coordinates and structure factors of VSG3 have been uploaded to the RCSB PDB (www.rcsb.org) with PDB ID: 6ELC.
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Sample size
We did not have an a priori prespecified effect size from which to preemptively determine an appropriate sample size for our mouse infection experiments ( Fig. 4 and Supplementary Figs. 8 and 9 ) but the sample sizes were large enough to detect the effect observed and to verify reproducibility. Also see statement in Methods, page 19.
Data exclusions No data were excluded.
Replication
Non-immunized mouse infection findings were reproduced for a total of n = 15 mice/experimental group (Figure 4a and b and Supplementary  Fig. 8a-d) as well as n = 6 mice/experimental group for a different mouse strain (Extended Data Fig8e-f). Pre-immunized mouse infection findings were reproduced for n = 12 mice / experimental group ( Fig. 4c and Supplementary Fig. 9a ). Antibody binding assays were reproduced with 3 independent mouse-derived antiserum samples for each experimental group. All results were found to be reproducible.
Randomization Mice were assumed to be sufficiently randomized by Jackson Laboratory and no additional randomization was performed.
Blinding
Experimenters were not blinded to mouse group allocation, but measurements (survival assessment, parasitemia counts, FACS MFI) were not subjective.
Reporting for specific materials, systems and methods We have used our own monoclonals for screening VSG3 and VSG3 mutant knock inclones (reported in PMID: 22952449 and mad e freely available to the community since then, through the monoclonal antibody facility of Rockefeller University).
Validation
These antibodies were initially validated in PMID: 22952449, and have been used in multiple subsequent studies (e.g. PMCID: PMC5635023).
